Small molecules called immunomodulators can help create more effective vaccines and stronger immunotherapies to treat cancer.
TLM-006 by Therillume for Glioblastoma Multiforme (GBM): Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes